Clinical Trials Logo

Burns clinical trials

View clinical trials related to Burns.

Filter by:

NCT ID: NCT00978419 Completed - Burns Clinical Trials

Pilot Trial of Statin Use in Burn Patients

BURNSTAT
Start date: March 2010
Phase: Phase 2
Study type: Interventional

This is a 90 day study, with patients receiving either oral Rosuvastatin or placebo for up to 28 days. The study will assess the affect of statins administered soon after burn injury on C-reactive protein (CRP) levels, patient mortality and the incidence of septic shock. The investigators also seek to describe the correlation between exposure to statins and development of delirium and de-novo long-term cognitive impairment. Hypothesis: 1. Statin administration within 96 hours of burn is safe, will decrease CRP, and will decrease septic shock and mortality in burn patients. 2. The investigators hypothesize that burn patients will have a de-novo long term cognitive impairment at 3 months after burn. 3. The investigators hypothesize the use of statins in burn patients will reduce the development and the degree of cognitive impairment at 3 months post burn.

NCT ID: NCT00934947 Completed - Pain Clinical Trials

Burn Healing and Analgesia With Propranolol

BURN HELP
Start date: July 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the ability of propranolol to decrease pain and improve recovery in burn patients with a common genotype.

NCT ID: NCT00898521 Completed - Burn Clinical Trials

Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns

Start date: December 20, 2009
Phase: Phase 2
Study type: Interventional

Burns represent one of the most severe and dreaded traumas. Burned and traumatized tissue is known as eschar. The dead eschar, if not removed, often becomes heavily contaminated and is the source of local and/or systemic infection or sepsis. The local inflammation and infection destroy healthy surrounding tissues and extends the original damage. In order to prevent these complications, and in order to minimize the risk of infection, it is imperative to evaluate the burn and remove all of the offending eschar at the earliest possible opportunity. This removal of dead tissue is termed "debridement". The most direct debridement method for eschar removal is surgery. Traditional, conservative non-surgical debridement is a lengthy process which often involves many complications. The objectives of this study are as follows: 1. To evaluate the safety and efficacy (exploratory) of DGD in hospitalized patients with Partial Thickness (mid and deep dermal) thermal burns of 4-30% total body surface area (TBSA), but with total burn wounds of no more than 30% TBSA. Measures have already been taken in previous studies involving deeper wounds to control safety parameters (such as pain, fever and infection). Nevertheless, as part of the effort to expand the burn population in the future phase 3 study to the more superficial wound group, it is important to first explore these parameters in a small group involving this burn population. 2. To explore DGD absorption as measured by Pharmacokinetic testing.

NCT ID: NCT00879723 Completed - Burn Clinical Trials

Burn Micronutrient Repletion Pilot Study

Start date: August 2010
Phase: Phase 1
Study type: Interventional

Burn injury patients undergo a series of metabolic changes that, if untreated, could lead to reduced health outcomes. Nutrition is thought to play a vital role in post-burn recovery. The research team developed a novel vitamin and mineral supplementation protocol based on current scientific literature. The study will test the hypothesis that the novel vitamin and mineral supplement regimen will improve adult patient recovery from burn injury.

NCT ID: NCT00875537 Completed - Clinical trials for Burning Mouth Syndrome

Neurogenic Mechanisms in Burning Mouth Syndrome

BMS17
Start date: January 2009
Phase: N/A
Study type: Interventional

Burning mouth syndrome (BMS) is characterized by a bilateral burning sensation in the anterior tongue, hard palate and lips in the absence of any clinical or laboratory findings. The term syndrome implicates the simultaneous presence of oral dryness (xerostomia) and altered taste (dysgeusia) in addition to the burning sensation in the oral mucosa. BMS is most often seen in women and is more frequent during menopause. The etiology and pathogenesis are still unclear but recent studies suggest that BMS is a neuropathic pain condition. The objectives of the study are: - To clarify potential neurogenic mechanisms behind BMS using immunohistochemistry (IH) to characterize the localization and distribution of peripheral nerve fibres, neuropeptides like substance P, calcitonin gene-related peptide, nerve growth factor, nerve growth factor receptor, PGP 9.5 neuronal marker and TRPV1 as well as inflammatory/structural changes. - To perform a randomized double blind cross-over intervention study to examine the efficacy and safety of topical application of capsaicin oral gel (on the tongue) to relieve the burning sensation in patients with BMS.

NCT ID: NCT00862576 Completed - Clinical trials for Burning Mouth Syndrome

A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome

Start date: June 2006
Phase: N/A
Study type: Observational

This is a case control study of the association between burning mouth syndrome and sleep dysfunction. Cases will comprise of patients diagnosed with burning mouth syndrome at the UCSF oral medicine clinic. Controls will include patients with leukoplakia, pigmented lesions, traumatic lesions, benign tumors, mucoceles, and pemphigoid matched on age (5 years) and gender to the cases. New patients as well as those presenting for follow-up visits will be eligible. Each case and control subject will be administered the following 4 questionnaires by interview: (1) enrollment questionnaire (2) Sleep scale from the medical outcomes study (MOS), (3) current sleep status scale and (4) a numerical rating scale for measurement of oral symptoms. Cases (BMS patients) will be followed in the clinic or by telephone contact once per month for the following 6 months and questionnaires 1 (question 6 only), 2, 3 and 4 will be administered by interview.

NCT ID: NCT00858442 Completed - Burns Clinical Trials

Platelet-Rich Plasma (PRP) in Reconstructive Surgery on Children With Retractable Burn Sequelae on Extremities

Start date: March 2009
Phase: N/A
Study type: Interventional

Does the addition of Platelet-Rich Plasma (PRP) to release of burn contractures and skin graft on the limbs of children with retractable burn sequelae reduce the initial time of the compressive treatment and maintain or lower the graft's retraction?

NCT ID: NCT00832156 Completed - Burns Clinical Trials

Application of Cultured Autologous Keratinocytes for Burn Wound Healing

KC
Start date: June 2008
Phase: Phase 3
Study type: Interventional

In this study the treatment of full thickness burn wounds with cultured autologous keratinocytes in combination with meshed split skin autograft versus meshed split skin graft alone will be compared. It is expected that the application of cultured autologous keratinocytes in combination with a meshed split skin autograft will improve wound healing and scar formation.

NCT ID: NCT00794742 Completed - Burns Clinical Trials

Antimicrobial Resistance of Bacteria in Burn Patients

Start date: November 2008
Phase: N/A
Study type: Observational

The purpose of this study is to test the resistance of pathogenic bacteria in infected tissues of burn patients to various antimicrobials and enzyme debriders.

NCT ID: NCT00787592 Completed - Burns Clinical Trials

SSD vs Collagenase in Pediatric Burn Patients

Start date: January 2008
Phase:
Study type: Observational

The objective of this study is to evaluate the outcomes of children with burn injury with regard to the utilization of Silver sulfadiazine (SSD) cream and Collagenase ointment. The primary outcome variable will be need for skin grafting. The specific aim of the study is to prospectively collect data to determine if SSD is superior to Collagenase with regard to avoiding the need for skin grafting.